Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Armata Pharmaceuticals, Inc.

Get SEC filing alerts via email and in your feed for Armata Pharmaceuticals, Inc.

ARMP

Armata Pharmaceuticals, Inc.

About Armata Pharmaceuticals, Inc.

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company developing high-purity, pathogen-specific bacteriophage therapeutics targeting antibiotic-resistant bacterial infections. Its lead candidates, AP-PA02 and AP-SA02, focus on chronic pulmonary infections caused by Pseudomonas aeruginosa and acute Staphylococcus aureus bacteremia, respectively. Utilizing proprietary phage discovery, engineering, and cGMP manufacturing, Armata aims to offer safer, targeted alternatives to broad-spectrum antibiotics for difficult-to-treat infections in specialized patient populations.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Armata Pharmaceuticals, Inc.

1
1
Armata Pharmaceuticals, Inc. Armata Pharmaceuticals Reports $115.3 Million Net Loss and Seeks Funding Amid Financial Challenges

Via official filing (AI summary) | 22 days ago | 0 comments

2
1
Armata Pharmaceuticals, Inc. Armata Pharmaceuticals Reports $173.8 Million Net Loss and Advances Clinical Trials in Latest 10-K Filing

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Armata Pharmaceuticals, Inc. Armata Pharmaceuticals Reports $26.7 Million Net Loss in Q3 2025, Seeks Additional Funding

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Armata Pharmaceuticals, Inc. Armata Pharmaceuticals Reports $16.3 Million Net Loss in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Armata Pharmaceuticals, Inc. Armata Pharmaceuticals Reports Q1 2025 Financial Results, Net Loss Reduced to $6.5 Million

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Armata Pharmaceuticals, Inc. Armata Pharmaceuticals Reports $18.9 Million Net Loss, Improves from Previous Year

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Armata Pharmaceuticals, Inc. Armata Pharmaceuticals Reports 142.7% Increase in Grant Revenue, Net Loss Decrease in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments